Credit Suisse Group reaffirmed their neutral rating on shares of Alder Biopharmaceuticals (NASDAQ:ALDR) in a research note published on Tuesday, BenzingaRatingsTable reports. They currently have a $19.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $11.00.

A number of other analysts also recently issued reports on ALDR. Leerink Swann assumed coverage on shares of Alder Biopharmaceuticals in a report on Tuesday, May 28th. They set an outperform rating and a $21.00 price objective for the company. ValuEngine raised shares of Alder Biopharmaceuticals from a hold rating to a buy rating in a report on Monday, September 16th. Morgan Stanley raised shares of Alder Biopharmaceuticals from an underweight rating to an equal weight rating and boosted their price target for the stock from $15.00 to $18.00 in a research note on Monday, September 16th. Canaccord Genuity downgraded shares of Alder Biopharmaceuticals from a buy rating to a hold rating and set a $20.00 price target for the company. in a research note on Monday, September 16th. Finally, Svb Leerink began coverage on shares of Alder Biopharmaceuticals in a research note on Tuesday, May 28th. They issued an outperform rating for the company. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of Hold and an average price target of $17.61.

NASDAQ ALDR opened at $18.64 on Tuesday. Alder Biopharmaceuticals has a 52-week low of $8.39 and a 52-week high of $18.90. The company has a quick ratio of 8.94, a current ratio of 8.94 and a debt-to-equity ratio of 1.74. The company has a fifty day moving average of $10.20 and a 200-day moving average of $11.59.

Alder Biopharmaceuticals (NASDAQ:ALDR) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.27. On average, analysts anticipate that Alder Biopharmaceuticals will post -4.13 earnings per share for the current year.

In other Alder Biopharmaceuticals news, Director Jeffrey T. L. Smith sold 32,728 shares of the business’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $18.44, for a total value of $603,504.32. Following the transaction, the director now owns 27,999 shares in the company, valued at $516,301.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 15.40% of the stock is currently owned by insiders.

Several hedge funds have recently added to or reduced their stakes in ALDR. Dimensional Fund Advisors LP increased its position in shares of Alder Biopharmaceuticals by 22.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,162,005 shares of the biopharmaceutical company’s stock valued at $11,910,000 after acquiring an additional 215,098 shares during the period. Rhumbline Advisers increased its position in shares of Alder Biopharmaceuticals by 10.3% in the first quarter. Rhumbline Advisers now owns 107,797 shares of the biopharmaceutical company’s stock valued at $1,471,000 after acquiring an additional 10,035 shares during the period. TD Asset Management Inc. increased its position in shares of Alder Biopharmaceuticals by 4.2% in the first quarter. TD Asset Management Inc. now owns 220,064 shares of the biopharmaceutical company’s stock valued at $3,004,000 after acquiring an additional 8,881 shares during the period. Fosun International Ltd increased its position in shares of Alder Biopharmaceuticals by 26.5% in the first quarter. Fosun International Ltd now owns 233,858 shares of the biopharmaceutical company’s stock valued at $3,113,000 after acquiring an additional 49,045 shares during the period. Finally, DekaBank Deutsche Girozentrale increased its position in shares of Alder Biopharmaceuticals by 22.2% in the first quarter. DekaBank Deutsche Girozentrale now owns 24,200 shares of the biopharmaceutical company’s stock valued at $432,000 after acquiring an additional 4,400 shares during the period.

About Alder Biopharmaceuticals

Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine.

Further Reading: Bar Chart

Analyst Recommendations for Alder Biopharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.